Navigation Links
Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
Date:4/16/2009

SOUTH SAN FRANCISCO, Calif., April 16 /PRNewswire/ -- Proteolix, Inc. today announced the appointment of Craig C. Parker to the post of Senior Vice President, Finance and Corporate Development and Chief Financial Officer (CFO), and the expansion of the company's clinical development and regulatory leadership team with the appointment of Michael G. Kauffman, M.D., Ph.D., to the post of Chief Medical Officer (CMO) and Albert L. Kraus, Ph.D., to the newly-created position of Vice President, Regulatory Affairs and Quality Assurance.

"We are pleased to welcome Craig Parker and Drs. Kauffman and Kraus to the Proteolix team at this important stage in the company's maturation. Craig's rich experience in finance, management and forming partnerships make him a superb addition as we advance our lead anti-cancer product, carfilzomib, into late-stage clinical studies," said John A. Scarlett, M.D., Proteolix's President and Chief Executive Officer. "In addition, the expansion of our clinical development leadership team reflects the excellent progress made in carfilzomib's development. Michael's background as program leader in the development of VELCADE, combined with his knowledge of carfilzomib as a prior member of the Proteolix Board of Directors, and Albert's experience in regulatory affairs and shepherding the late-stage development of new oncology therapeutics, will be invaluable as Proteolix advances carfilzomib through pivotal clinical trials."

Craig C. Parker

Senior Vice President, Finance and Corporate Development and Chief Financial Officer

Mr. Parker brings more than 15 years of finance and business development leadership in the biotechnology industry to Proteolix. In this newly-created role, he is responsible for the company's financial operations, business development, corporate strategic planning and legal affairs.

Mr. Parker's career includes 12 years as a Wall Street research analyst. From 2002 - 2007, he was a Managing Director and head of Biotechnology Equity Research at Lehman Brothers. Mr. Parker also covered the biotechnology industry as the senior biotechnology analyst at Donaldson, Lufkin & Jenrette from 1998 - 1999, and as an analyst at JP Morgan from 1994-1998. He was consistently rated one of the top analysts covering the biotechnology sector by Institutional Investor, Reuters, and Greenwich Research surveys, and was also a Wall Street Journal All-Star Analyst. His additional investment experience includes serving as a Partner at Sprout Group, the venture capital affiliate of CSFB, from 2001 - 2002, where he also represented the firm on the boards of Picoliter, Gryphon Therapeutics, and Xcyte.

Mr. Parker's operating experience includes serving as Senior Vice President and General Manager of the Specialty Therapeutics Franchise at Immunex Corporation from 1999 - 2001. In that capacity, he managed the discovery, development, manufacture and marketing for Immunex oncology and neurology products.

Mr. Parker received his undergraduate degree in Biological Sciences from the University of Chicago, an MBA from the University of Michigan Stephen M. Ross School of Business, and attended the Georgetown University School of Medicine.

Michael G. Kauffman, M.D., Ph.D.

Chief Medical Officer

Dr. Kauffman, previously a member of Proteolix's Board of Directors, was a clinical developer of the proteasome inhibitor VELCADE(R) at Millennium Pharmaceuticals (now a subsidiary of Takeda Pharmaceutical Company). As CMO, he will be responsible for the advancement of carfilzomib, Proteolix's lead anti-cancer proteasome inhibitor for the treatment of multiple myeloma and other cancers, through late-stage clinical development. In addition, Dr. Kauffman will oversee the clinical development of Proteolix's earlier-stage proteasome inhibitor programs, including PR-047, an oral proteasome inhibitor for the treatment of cancer.

Most recently, Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008. From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc. Dr. Kauffman also served as Medical Director at Biogen Corporation (now Biogen Idec).

Dr. Kauffman received an M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins and holds a B.A. in biochemistry from Amherst College. He trained in Internal Medicine and Rheumatology at Beth Israel Deaconess Hospital and the Massachusetts General Hospital.

Albert L. Kraus, Ph.D.

Vice President, Regulatory Affairs and Quality Assurance

Dr. Kraus joins Proteolix with more than 20 years of pharmaceutical industry experience in overseeing drug development and regulatory strategy, particularly for novel oncology products. In his new role, Dr. Kraus will be responsible for regulatory affairs and quality assurance, including registration development strategy and the company's interactions with the FDA and regulatory bodies outside the United States.

Dr. Kraus joins Proteolix from Kosan Biosciences (acquired by Bristol-Myers Squibb in 2008), where he served as Vice President, Regulatory Affairs and Development while overseeing the clinical development strategy of Kosan's oncology product portfolio. Prior to joining Kosan in 2006, he was Group Director, Global Regulatory Strategy, Oncology with Bristol-Myers Squibb. While there, he led Bristol-Myers Squibb's oncology regulatory strategy organization, with worldwide responsibilities for new drug development, licensing support, registration strategy and execution, and post-marketing support. In his tenure with Bristol-Myers Squibb, he also held positions of Director, Regulatory Science Europe and Associate Director, Worldwide Regulatory Affairs. Previously, he held positions of Section Head, Toxicology, Human Safety and Regulatory Services for Procter & Gamble and Group Leader and Section Head of Pharmacology, Toxicology and Human Safety at Richardson Vicks, a Procter & Gamble company.

Dr. Kraus holds a Ph.D. in biochemical toxicology from the University of Michigan and a B.A. in biology and economics from Hamilton College.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of highly specific proteasome inhibitors, and is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in multiple myeloma and other malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit www.proteolix.com.

    Contact information
    Investors:                            Media Inquiries:
    Craig C. Parker                       BCC Partners
    Senior Vice President, Finance and    Karen L. Bergman or Michelle Corral
    Corporate Development & Chief         650-575-1509 or 415-794-8662
    Financial Officer
    650-266-2682


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):